SCHEMBL16070591

SCHEMBL16070591

C#Cc1ccc([C@H](O)CO)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.38
HDAC8 Q9BY41 2/20 0.37
TAAR1 Q96RJ0 3/20 0.34
HIF1A Q16665 2/20 0.34
HTR3A P46098 1/20 0.34
NFKB1 P19838 1/20 0.34
KDM4E B2RXH2 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
ALOX15 P16050 1/20 0.33
APEX1 P27695 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
PLAU P00749 1/20 0.33
AOC3 Q16853 2/20 0.32
PTPN1 P18031 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16070594 1.00 TSHR (0.38) TSHRCYP3A4HDAC8TAAR1HIF1A
SCHEMBL16070578 1.00 TSHR (0.38) TSHRCYP3A4HDAC8TAAR1HIF1A
SCHEMBL16070643 0.83 HDAC8 (0.34) TSHRHDAC8TAAR1HIF1AHTR3A
SCHEMBL16070657 0.83 HDAC8 (0.34) TSHRHDAC8TAAR1HIF1AHTR3A
SCHEMBL16070651 0.83 HDAC8 (0.34) TSHRHDAC8TAAR1HIF1AHTR3A
SCHEMBL16070593 0.82 HDAC8 (0.33) TSHRHDAC8TAAR1HIF1AHTR3A
SCHEMBL16070608 0.82 HDAC8 (0.33) TSHRHDAC8TAAR1HIF1AHTR3A
SCHEMBL17518200 0.81 LMNA (0.54) TSHRCYP3A4HDAC8TAAR1HIF1A
SCHEMBL13849426 0.81 LMNA (0.54) TSHRCYP3A4HDAC8TAAR1HIF1A
SCHEMBL17438169 0.81 TSHR (0.48) TSHRCYP3A4TAAR1HIF1AHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200308105-A1 NOVEL METHOD FOR PRODUCING HYDROXAMIC ACID DERIVATIVE, AND INTERMEDIATE THEREFOR FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) 2020-10-01 US disclosed
US-20200308105-A1 NOVEL METHOD FOR PRODUCING HYDROXAMIC ACID DERIVATIVE, AND INTERMEDIATE THEREFOR FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) 2020-10-01 US disclosed
US-20200308103-A1 NOVEL CRYSTALS OF HYDROXAMIC ACID DERIVATIVE, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION TOYAMA CHEMICAL CO., LTD. (JP) 2020-10-01 US disclosed
US-20200308103-A1 NOVEL CRYSTALS OF HYDROXAMIC ACID DERIVATIVE, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION TOYAMA CHEMICAL CO., LTD. (JP) 2020-10-01 US disclosed
US-20200062789-A1 HYDROXAMIC ACID PRODRUG COMPOUND OR SALT THEREOF, LYOPHILIZED FORMULATION, LPXC INHIBITOR, AND ANTIBACTERIAL AGENT FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3192503-B1 NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2019-08-14 EP disclosed
EP-2975022-B1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2019-05-08 EP disclosed
US-20190054179-A1 NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2019-02-21 US disclosed
US-20190054179-A1 NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3438088-A1 CRYSTALS OF NOVEL HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION Toyama Chemical Co., Ltd. (JP) 2019-02-06 EP disclosed
EP-3192503-A1 NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2017-07-19 EP disclosed
EP-3192505-A1 METHOD FOR USING NOVEL HYDROXAMIC ACID DERIVATIVE AND ANTIBACTERIAL SUBSTANCE IN COMBINATION TOYAMA CHEMICAL CO., LTD. (JP) 2017-07-19 EP disclosed
EP-3192505-A1 METHOD FOR USING NOVEL HYDROXAMIC ACID DERIVATIVE AND ANTIBACTERIAL SUBSTANCE IN COMBINATION TOYAMA CHEMICAL CO., LTD. (JP) 2017-07-19 EP disclosed
EP-3192503-A1 NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2017-07-19 EP disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
EP-2975022-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2016-01-20 EP disclosed
EP-2975022-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2016-01-20 EP disclosed
WO-2014142298-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF 富山化学工業株式会社 (JP) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308103-A1 NOVEL CRYSTALS OF HYDROXAMIC ACID DERIVATIVE, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION HAAO, HACL2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TSHR 3768/4885CYP3A4 765/4885HDAC8 168/4885
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF H1-0, H1-2, HDAC1 TSHR 1820/4885CYP3A4 3086/4885HDAC8 30/4885
US-20200062789-A1 HYDROXAMIC ACID PRODRUG COMPOUND OR SALT THEREOF, LYOPHILIZED FORMULATION, LPXC INHIBITOR, AND ANTIBACTERIAL AGENT LCT, LPXN, HDAC1 TSHR 3092/4885CYP3A4 3984/4885HDAC8 52/4885
US-20200308105-A1 NOVEL METHOD FOR PRODUCING HYDROXAMIC ACID DERIVATIVE, AND INTERMEDIATE THEREFOR HADH, HDAC11, HADHA TSHR 3061/4885CYP3A4 1338/4885HDAC8 56/4885
US-20190054179-A1 NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF HAAO, HPD, HCAR2 TSHR 4400/4885CYP3A4 2793/4885HDAC8 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.